{"id":19385,"date":"2023-04-21T00:34:00","date_gmt":"2023-04-20T16:34:00","guid":{"rendered":"https:\/\/flcube.com\/?p=19385"},"modified":"2024-12-23T00:40:42","modified_gmt":"2024-12-22T16:40:42","slug":"jiangsu-aidea-pharmaceutical-secures-global-licensing-deal-for-kainos-medicines-hiv-drugs","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=19385","title":{"rendered":"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine&#8217;s HIV Drugs"},"content":{"rendered":"\n<p>Jiangsu Aidea Pharmaceutical Co., Ltd (<a href=\"https:\/\/www.google.com\/finance\/quote\/688488:SHA\">SHA: 688488<\/a>), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos&#8217; ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs globally, excluding the Chinese mainland, Hong Kong, Taiwan, and South Korea. In return, Aidea will pay Kainos royalties and profits based on varying ranges per region.<\/p>\n\n\n\n<p><strong>Building on an Existing Partnership<\/strong><br>This licensing deal expands upon an existing relationship between the two companies. Initially, they formed a partnership in November 2020 and established a joint venture (JV) named Kaidea Global Pte in Singapore in April 2021. The JV&#8217;s focus is on the overseas promotion of ACC007, a novel non-nucleoside reverse transcriptase inhibitor with a unique structure. ACC007 was approved in China in June 2021 for the treatment of primary HIV-1 infection patients and was included in the National Reimbursement Drug List (NRDL) in December of the same year.<\/p>\n\n\n\n<p><strong>ACC008&#8217;s Market Progression<\/strong><br>ACC008, another drug under the agreement, received approval in China in December of the previous year. This fixed dose combination therapy provides an additional option for the treatment of HIV-1 infection, further expanding the portfolio of available therapies in the global market.<a href=\"https:\/\/flcube.com\">-Fineline Info &amp; Tech<\/a><\/p>\n\n\n\n<p><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":false,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[619,631,2900,988],"class_list":["post-19385","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-aidea-pharmaceutical","tag-hiv-aids-care","tag-kainos-medicine","tag-sha-688488"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine&#039;s HIV Drugs - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos&#039; ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs globally, excluding the Chinese mainland, Hong Kong, Taiwan, and South Korea. In return, Aidea will pay Kainos royalties and profits based on varying ranges per region.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=19385\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine&#039;s HIV Drugs\" \/>\n<meta property=\"og:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=19385\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2023-04-20T16:34:00+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-12-22T16:40:42+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19385#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19385\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine&#8217;s HIV Drugs\",\"datePublished\":\"2023-04-20T16:34:00+00:00\",\"dateModified\":\"2024-12-22T16:40:42+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19385\"},\"wordCount\":228,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Aidea Pharmaceutical\",\"HIV \\\/ AIDS care\",\"Kainos Medicine\",\"SHA: 688488\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19385#respond\"]}],\"copyrightYear\":\"2023\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19385\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=19385\",\"name\":\"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine's HIV Drugs - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2023-04-20T16:34:00+00:00\",\"dateModified\":\"2024-12-22T16:40:42+00:00\",\"description\":\"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos' ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs globally, excluding the Chinese mainland, Hong Kong, Taiwan, and South Korea. In return, Aidea will pay Kainos royalties and profits based on varying ranges per region.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19385#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=19385\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=19385#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine&#8217;s HIV Drugs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine's HIV Drugs - Insight, China&#039;s Pharmaceutical Industry","description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos' ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs globally, excluding the Chinese mainland, Hong Kong, Taiwan, and South Korea. In return, Aidea will pay Kainos royalties and profits based on varying ranges per region.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=19385","og_locale":"en_US","og_type":"article","og_title":"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine's HIV Drugs","og_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","og_url":"https:\/\/flcube.com\/?p=19385","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2023-04-20T16:34:00+00:00","article_modified_time":"2024-12-22T16:40:42+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=19385#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=19385"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine&#8217;s HIV Drugs","datePublished":"2023-04-20T16:34:00+00:00","dateModified":"2024-12-22T16:40:42+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=19385"},"wordCount":228,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Aidea Pharmaceutical","HIV \/ AIDS care","Kainos Medicine","SHA: 688488"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=19385#respond"]}],"copyrightYear":"2023","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=19385","url":"https:\/\/flcube.com\/?p=19385","name":"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine's HIV Drugs - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2023-04-20T16:34:00+00:00","dateModified":"2024-12-22T16:40:42+00:00","description":"Jiangsu Aidea Pharmaceutical Co., Ltd (SHA: 688488), a China-based pharmaceutical company, has entered into a licensing agreement with South Korean firm Kainos Medicine Inc., concerning Kainos' ainuovirine (ACC007) and its fixed dose preparation ainuovirine, lamivudine, tenofovir disoproxil (ACC008). The agreement grants Aidea commercial, development, and promotion rights for these drugs globally, excluding the Chinese mainland, Hong Kong, Taiwan, and South Korea. In return, Aidea will pay Kainos royalties and profits based on varying ranges per region.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=19385#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=19385"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=19385#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Jiangsu Aidea Pharmaceutical Secures Global Licensing Deal for Kainos Medicine&#8217;s HIV Drugs"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19385","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=19385"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19385\/revisions"}],"predecessor-version":[{"id":19388,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/19385\/revisions\/19388"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=19385"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=19385"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=19385"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}